{
    "clinical_study": {
        "@rank": "13093", 
        "acronym": "PAPAL", 
        "arm_group": [
            {
                "arm_group_label": "Posaconazole - CF Participants", 
                "arm_group_type": "Experimental", 
                "description": "Posaconazole will be administered to approximately 20 lung transplant participants with CF."
            }, 
            {
                "arm_group_label": "Posaconazole - Non-CF Participants", 
                "arm_group_type": "Experimental", 
                "description": "Posaconazole will be administered to approximately 20 lung transplant participants without CF (non-CF)."
            }
        ], 
        "brief_summary": {
            "textblock": "This single site study will examine plasma and alveolar compartment (AC) levels of\n      posaconazole in cystic fibrosis (CF) and non-cystic fibrosis (non-CF) lung transplant\n      recipients receiving routine post-operative anti-fungal prophylaxis. Invasive fungal\n      infection rates will be assessed following transplantation."
        }, 
        "brief_title": "A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Fungal Infection", 
        "condition_browse": {
            "mesh_term": "Mycoses"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Scheduled to undergo lung transplantation\n\n          -  Able to take oral/nasogastric medication\n\n          -  Females of childbearing potential, males, and the sexual partners of males must use\n             an effective method of birth control during this study and for 6 weeks after\n             completing the study.\n\n        Exclusion Criteria:\n\n          -  Severe liver disease\n\n          -  Current use of cytochrome P-450 (CYP)-3A4 inhibitors including terfenadine,\n             astemizole, cisapride, pimozide, halofantrine or quinidine within 7 days before\n             transplant\n\n          -  Treatment with posaconazole within 14 days before transplant\n\n          -  Breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667107", 
            "org_study_id": "5592-105", 
            "secondary_id": "2012-003140-68"
        }, 
        "intervention": {
            "arm_group_label": [
                "Posaconazole - CF Participants", 
                "Posaconazole - Non-CF Participants"
            ], 
            "description": "Posaconazole 400 mg oral solution twice daily administered with Calogen\u00ae to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the patient is unable to meet the conditions for optimal absorption of posaconazole.", 
            "intervention_name": "Posaconazole", 
            "intervention_type": "Drug", 
            "other_name": [
                "SCH056592", 
                "MK-5592", 
                "Noxafil\u00ae"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Posaconazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 11, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Time to reach steady state plasma concentration of posaconazole", 
                "safety_issue": "No", 
                "time_frame": "Through Day 12"
            }, 
            {
                "measure": "Concentrations of posaconazole in plasma and alveolar compartment (AC)", 
                "safety_issue": "No", 
                "time_frame": "Through Day 41"
            }
        ], 
        "removed_countries": {
            "country": "United Kingdom"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667107"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of participants who develop invasive fungal infection", 
            "safety_issue": "No", 
            "time_frame": "Through Week 12 post transplant"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014", 
        "why_stopped": "Study terminated due to an unfavorable risk-benefit analysis"
    }
}